CSL Limited Sponsored ADR (OTCMKTS:CSLLY) Sees Significant Increase in Short Interest

CSL Limited Sponsored ADR (OTCMKTS:CSLLY) saw a significant growth in short interest in June. As of June 30th, there was short interest totaling 394,744 shares, a growth of 82.3% from the June 15th total of 216,478 shares. Based on an average daily volume of 1,137,720 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.0% of the company’s stock are sold short.

Analysts Set New Price Targets

A number of analysts have recently commented on the stock. Canaccord Genuity Group cut shares of CSL from a “strong-buy” rating to a “hold” rating in a report on Monday, May 11th. Zacks Research downgraded CSL from a “hold” rating to a “strong sell” rating in a research note on Monday, May 11th. Citigroup downgraded shares of CSL from a “strong-buy” rating to a “hold” rating in a report on Monday, May 11th. Finally, Jefferies Financial Group downgraded shares of CSL from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 29th. Four equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Reduce”.

CSL Trading Down 0.2%

OTCMKTS CSLLY opened at $21.43 on Friday. The company has a quick ratio of 1.15, a current ratio of 2.57 and a debt-to-equity ratio of 0.51. CSL has a 52 week low of $16.01 and a 52 week high of $44.85. The stock’s 50-day moving average price is $18.99 and its 200-day moving average price is $33.20.

CSL Company Profile

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.